-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Centralized procurement of Chinese patent medicines is imminent, and the anti-monopoly cloud is coming again
Centralized procurement of Chinese patent medicines is imminent, and the anti-monopoly cloud is coming againThe anti-monopoly sword came out again
On August 30, at the 21st meeting of the Central Committee for Comprehensively Deepening Reform, the "Opinions on Strengthening Anti-Monopoly and Deepening the Implementation of Fair Competition Policy" deliberated and passed
Strengthening anti-monopoly and deepening the implementation of fair competition policies are the inherent requirements for improving the socialist market economy system
The pharmaceutical industry is a key area of anti-monopoly this year
Since 2021, Simcere Pharmaceutical, Tianyao, and Yangzijiang Pharmaceutical have received huge fines due to monopoly
Under the new situation of increasing anti-monopoly noise, the road to control the sale of drugs will become narrower and narrower
Controlled sales model = monopoly
Controlled sales model = monopolyControlled sales is a sales model that pharmaceutical professionals are too familiar with.
Controlling sales also raised the price of medicines.
Controlling sales also raises the price of medicines.
The Harbin Pharmaceutical Sixth Factory, which was the first to get through the TV advertising sales code, was a master of sales control , while Sunflower Pharmaceutical, Amendment Pharmaceutical, and Renhe Pharmaceutical became the later three giants of pharmaceutical control and sales
The Harbin Pharmaceutical Sixth Factory, which was the first to get through the TV advertising sales code, was the three giants of pharmaceutical control and sales masters.
Another important task of controlling sales is to control online drug prices
In February 2021, Sichuan Meidakang Pharmaceutical stopped supplying several major e-commerce platforms because the online price of "Compound Pearl Mouth Granules" was three times lower than that of offline pharmacies
Sichuan Meidakang Pharmaceutical
Yangtze River's monopoly has been punished, which is regarded by the industry as a denial of the control and sales model of pharmaceutical companies
The industry sees it as a denial of the control and sales model of pharmaceutical companies
Where is the control of sales heading for the tightening of supervision?
Where is the control of sales heading for the tightening of supervision?Anti-monopoly clearly says no to the control and sales of the pharmaceutical industry, and the industry is also changing its face and continuing to control sales
The "Internet Controlled Sales Model" came into being.
The country's first Internet controlled drug direct sales network
"Pharmaceutical contract" is the representative of the Internet controlled sales model
A large number of Internet sales control platforms such as Shengxing Pharmaceutical and Pharma Elf
This is obviously contrary to the general policy trend
In March this year, the China Chemical and Pharmaceutical Industry Association issued the "Pharmaceutical Industry Compliance Management Regulations", and anti-monopoly was highlighted
Anti-monopoly in the field of medicine, in the final analysis, is to reduce the price of medicines to protect the interests of patients
A series of policies such as centralized procurement, two-invoice system, medical insurance negotiation, anti-corruption, credit evaluation system, etc.
, all remind pharmaceutical companies that it is not feasible to follow the old road blindly
.
On August 9, the National Medical Insurance Administration made it clear in its response to the suggestion: The next step is to scientifically and steadily advance the reform of centralized procurement of proprietary Chinese medicines and formula particles, oriented to clinical demand, and start with high-priced and large-volume varieties
.
From the perspective of the industry, it is necessary to use antitrust and other means to reduce the market price of medicines before the development of centralized procurement of more varieties of Chinese patent medicines
.
The era of barbaric growth in the pharmaceutical industry is not over yet, but it will always pass
.
